Fulcrum Therapeutics, Inc. Common Stock (FULC) is a publicly traded Healthcare sector company. As of May 21, 2026, FULC trades at $6.35 with a market cap of $405.80M and a P/E ratio of -39.05. FULC moved +7.45% today. Year to date, FULC is -41.42%; over the trailing twelve months it is -2.46%. Its 52-week range spans $2.32 to $15.74. Analyst consensus is buy with an average price target of $18.44. Rallies surfaces FULC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Fulcrum Therapeutics Posts $0.25 Q1 Loss, Plans H2 2026 Pociredir Trial: Fulcrum posted a Q1 net loss of $18.9 million ($0.25/share), beating the $0.30/share forecast, and its shares rose 2.81% pre-market. The company highlighted strong fetal hemoglobin induction from pociredir, plans a H2 2026 registration-enabling trial, and holds $333.3 million cash runway into 2029.
| Metric | Value |
|---|---|
| Price | $6.35 |
| Market Cap | $405.80M |
| P/E Ratio | -39.05 |
| EPS | $-0.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.74 |
| 52-Week Low | $2.32 |
| Volume | 12.03K |
| Avg Volume | 0 |
| Revenue (TTM) | $80.00M |
| Net Income | $-9.72M |
| Gross Margin | 0.00% |
9 analysts cover FULC: 0 strong buy, 7 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.44.